Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck’s Heart Failure Drug Flunks Phase III

This article was originally published in The Pink Sheet Daily

Executive Summary

Rolofylline fails to meet primary and secondary endpoints in a Phase III trial.

You may also be interested in...



Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline

The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.

Vorapaxar Woes Increase Pressure On Remainder Of Merck CV Pipeline

The mid-January announcement that Merck & Co. was ending one pivotal trial and removing patients with a history of stroke from another for Phase III anti-clotting agent vorapaxar has called into question the pharma’s continued heavy emphasis on cardiovascular research and development.

Where Are They Now? Checking In On Four Cardiovascular Start-Ups

It's no secret increasing generic competition and regulatory oversight, combined with the financial challenges of developing a primary care drug, make cardiovascular a tough place for venture-backed biotechs. START-UP takes the pulse of four previously profiled cardiovascular companies -- arca Biopharma, Celladon, NovaCardia and Portola Pharmaceuticals, -- to see what lessons they've learned.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel